Free tool
FAERS Monitor: Yusimry
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761216 or its brand name (Yusimry, Adalimumab-Aqvh). Reports on generic versions are filed under their own applications.
Reports
99
Serious
25
25% of reports
Hospitalization
9
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- accidental exposure to product34
- product dose omission issue31
- device malfunction28
- no adverse event15
- device leakage11
- product quality issue9
- product complaint6
- drug ineffective5
- device failure4
- device issue4
- incorrect dose administered4
- pain4
- product leakage4
- device defective3
- device difficult to use3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 23 |
| 2024 | 34 |
| 2025 | 25 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,060 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product leakageSignal | 4 | 151.6 | 58.0 | 457 |
| device malfunctionSignal | 28 | 84.7 | 61.9 | 2,239 |
| accidental exposure to productSignal | 34 | 70.1 | 53.4 | 2,258 |
| device failureSignal | 4 | 55.8 | 21.4 | 164 |
| device leakageSignal | 11 | 53.9 | 30.9 | 521 |
| product complaintSignal | 6 | 50.3 | 23.2 | 243 |
| device defectiveSignal | 3 | 36.8 | 12.1 | 72 |
| product dose omission issueSignal | 31 | 22.4 | 16.7 | 621 |
| no adverse eventSignal | 15 | 17.6 | 11.0 | 220 |
| product quality issueSignal | 9 | 14.1 | 7.6 | 97 |
| device difficult to useSignal | 3 | 9.6 | 3.2 | 15 |
| device issueSignal | 4 | 9.5 | 3.6 | 23 |
| incorrect dose administeredSignal | 4 | 3.7 | 1.4 | 6 |
| pain | 4 | 1.4 | 0.5 | 0 |
| drug ineffective | 5 | 0.8 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.